NCT04541134View on ClinicalTrials.gov

Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

PHASE3UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Primary Dysmenorrhea
Interventions
DRUG

Pelubiprofen 45mg

Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)

DRUG

Placebo

Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

NCT04541134 - Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea | Biotech Hunter | Biotech Hunter